Silence Therapeutics Plc Stock Analysis

Silence Stock Analysis Notes

About 17.0% of the company outstanding shares are owned by corporate insiders. The book value of Silence Therapeutics was at this time reported as 0.43. The company recorded a loss per share of 1.76. Silence Therapeutics PLC had not issued any dividends in recent years. Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid therapeutics in hematology, cardiovascular, and other rare and metabolic indications. Silence Therapeutics plc is headquartered in London, the United Kingdom. Silence Therapeutics is traded on NASDAQ Exchange in the United States. To find out more about Silence Therapeutics PLC contact MBA MBA at 44 20 3457 6900 or learn more at https://www.silence-therapeutics.com.

Silence Therapeutics PLC Investment Alerts

Silence Therapeutics PLC Upcoming and Recent Events

Silence Largest EPS Surprises

View All Earnings Estimates

Silence Therapeutics Environmental, Social, and Governance (ESG) Scores

Silence Stock Institutional Investors

Note, although Silence Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Silence Market Capitalization

The company currently falls under 'Small-Cap' category with a total capitalization of 354.11 M.

Silence Profitablity

The company has Net Profit Margin of (2.24) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (30.64) %, which entails that for every $100 of revenue, it lost $30.64.

Management Efficiency

Silence Therapeutics PLC has Return on Asset of (0.2154) % which means that on every $100 spent on assets, it lost $0.2154. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6428) %, meaning that it generated no profit with money invested by stockholders. Silence Therapeutics' management efficiency ratios could be used to measure how well Silence Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of December 2024, Return On Tangible Assets is likely to drop to -0.53. In addition to that, Return On Capital Employed is likely to drop to -0.68. At this time, Silence Therapeutics' Fixed Asset Turnover is very stable compared to the past year. As of the 13th of December 2024, Asset Turnover is likely to grow to 0.28, while Non Current Assets Total are likely to drop about 8.2 M.

Technical Drivers

As of the 13th of December 2024, Silence Therapeutics has the Variance of 37.88, coefficient of variation of (461.79), and Risk Adjusted Performance of (0.15). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Silence Therapeutics PLC, as well as the relationship between them.

Silence Therapeutics PLC Price Movement Analysis

Silence Therapeutics Outstanding Bonds

Silence Therapeutics Predictive Daily Indicators

Silence Therapeutics Corporate Filings

Silence Therapeutics Forecast Models

Silence Therapeutics' time-series forecasting models are one of many Silence Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Silence Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Silence Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Silence shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Silence Therapeutics. By using and applying Silence Stock analysis, traders can create a robust methodology for identifying Silence entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Silence analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Silence analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Silence Therapeutics PLC stock analysis indicators help investors evaluate how Silence Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Silence Therapeutics shares will generate the highest return on investment. By understating and applying Silence Therapeutics stock analysis, traders can identify Silence Therapeutics position entry and exit signals to maximize returns.

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silence Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silence Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silence Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.